Introduction:

In May 2020, cases of a disease that shared clinical and analytical features with Kawasaki disease were documented in the United Kingdom and the United States, which were associated with immune dysregulation secondary to a recent SARS-CoV-2 infection.

Objective:

To communicate the experiences of the evolution and treatment of a patient diagnosed with this new disease.

Case presentation:

A 17-year-old teenager with a history of COVID-19 six weeks ago. He was admitted with mucocutaneous lesions, polypnea, tachycardia, jaundice and asthenia. Two hours after arriving at the intensive care unit, he presented pulseless ventricular tachycardia, of which he did two events that required advanced cardiopulmonary resuscitation. Inotropic support was required for several days due to myocardial involvement. After 72 hours with a left ventricular ejection fraction below 35%, he began to improve until complete recovery. He received treatment with IV methylprednisolone and the Cuban immunoregulatory peptide jusvinza.

Conclusions:

The multisystem inflammatory syndrome associated with COVID-19, presented for the first time in the province of Cienfuegos, is a new condition, which is usually serious and requires intensive care because it produces organic dysfunction, but above all cardiac involvement. It has a clinical presentation similar to more common diseases, so it is essential to be alert for a timely diagnosis that guarantees the success of treatment and prevents death.

        · resumen en Español     · texto en Español     · Español ( pdf )